William Greene, M.D.
Managing Director, Genentech

Dr. Greene joined MPM's San Francisco office in 2002. Prior to MPM, he was at Genentech where from 1998 - 2002 he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and management, regulatory interactions and safety monitoring spanning several therapeutic areas including leading the early clinical development of Lucentis®. From 1991-1998, Dr. Greene was at Yale Medical School where he trained in Internal Medicine and Diagnostic Radiology, taught medicine and did clinical research. Dr. Greene has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He is a member of the American College of Physicians and the Society for Clinical Epidemiology and Health Care Research, has published widely, taught and practiced medicine, and received awards for clinical research excellence. He received a BA degree from Wesleyan University (biology) and an MD degree from UCSF.

Current Boards: Allozyne, Inc. (Observer);; EndoGastric Solutions, Inc.; Neovista, Inc.; Sai Advantium Pharma, Ltd.

Past Boards: Alsius Corp. (NASDAQ:ALUS); Archus Orthopedics, Inc., Barrier Therapeutics, Inc. (NASDAQ:BTRX) (Observer); CoTherix, Inc. (Observer); Idun Pharmaceuticals, Inc. (Observer); Intercell AG (VSE:ICLL); QuatRx Pharmaceuticals Company; Synergia Pharma, Inc.; Verus Pharmaceuticals, Inc. (Observer); VLST Corp. (Observer)